Pharmaceuticals & Therapeutics

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

A UK spinout just raised £2M for an eye-drop that becomes a healing bandage on contact. This could disrupt a $12B market and offer hope for rare diseases.

With a promising osteoarthritis drug in late-stage trials, Levicept hires a CFO known for Nasdaq listings and M&A, signaling a major financial move.

Aligos Therapeutics secures a key partnership and regulatory fast-track in China, signaling a major financial and clinical validation for its novel HBV drug.

Vertex's new CF drug, ALYFTREK, clears a major hurdle in Canada, promising a once-daily treatment and new hope for patients previously left behind.

With a breakthrough oral drug for a rare form of blindness, Belite Bio heads to a key symposium. Can it convince investors it can win a crowded race?

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

After a Health Canada-mandated pause, LSL's Steri-Med is near full remediation. This is more than a fix—it’s a calculated play for North American market leadership.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

A $250 credit for hormone therapy seems generous, but a closer look at SynergenX's '250 for 250' initiative reveals a sophisticated marketing strategy.

At Boston's Wedbush Renal Summit, Hansa Biopharma showcases its game-changing transplant drug, signaling a major strategic play for the lucrative U.S. market.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

Advicenne's unlimited UK drug approval for Sibnayal® is a win for rare disease patients, but it's one piece in a high-stakes global strategy now targeting the US market.

Artelo's latest data on its non-opioid pain drug ART26.12 could unlock a massive market, but what are the real risks and rewards for this clinical-stage biotech?

Vyome Holdings secures a key patent in China, not by betting the farm, but by making a shrewd, capital-efficient move to tap into a massive future market.

New imaging data provides the first evidence that a drug-app combo for Parkinson's can induce physical changes in the brain, linking digital therapy to better outcomes.

Galderma's innovative neuromodulator, a key to its 'powerhouse' ambitions, hits a U.S. roadblock. The FDA's concerns? Manufacturing, not safety.

The FDA approved Orca Bio's revolutionary cell therapy, promising better outcomes for cancer patients. But the real test lies beyond the science.